James Noble is taking his last lap at the biotech he founded, and saved. It's Adrian Rawcliffe's turn now
Back in the summer of 2014, Adaptimmune CEO James Noble had about a million pounds in the bank. Not too much to survive on, as he told me later in recounting the tale. But after steering the startup in and out of a buyout in order to stay in business, it wasn’t his first look over the cliff.
A few months later GlaxoSmithKline stepped up with a $350 million collaboration deal, where it is still actively involved in pushing through a leading program in the T-cell receptor (TCR) field.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.